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measurements of clinical values. CONCLUSIONS: Almost 75%
of subjects with hypertension were aware of it. However, control
rate was relatively low in this Latino population, suggesting 
a need for community-based programs targeting hypertensives
unaware of their diagnosis.
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OBJECTIVE: To know the cost implications of antihypertensive
therapy to society. METHOD: Cost of Illness Analysis was used
for Out-Patients. Drug review was carried out retrospectively for
randomly sampled 39 case notes over a one-year period. The fol-
lowing were collected; number of hospital visits, BP at each visit,
drugs prescribed at each visit. Cost components were the direct
medical costs. These include the total cost of drugs over one-year
period, personnel cost, diagnostic costs, and transport cost. Hos-
pital cost of the drugs were used and the cost per deﬁned daily
dose of each drug was calculated as well as the total drug cost
for one year. Stop-watch-time studies and monthly earnings were
used in the calculation of personnel costs for each patient bearing
in mind the number of visits. Since the study covers a one-year
period (July, 2003–July, 2004), neither discounting nor inﬂation
were considered in the analysis. RESULTS: Combination therapy
was used for all patients. Total cost of therapy for the 39 patients
over a one year period = N1,391,528.35 (US$9939.49), 90.4%
(N1,258,139.35; US$8986.71) of which was for drugs. Average
cost per patient = N35,680.21, range of cost; N1,026.80 and
N84,395.15. With prevalence of hypertension in Nigeria esti-
mated to be 10%–12% (132.8 million according to UNDP
2004); total Cost of Illness associated with hypertension less the
indirect costs among others not considered could be in the range
of N473,142,628,800.00 i.e. over N450 billion (over US$3.38
billion) per annum. CONCLUSION: The cost of illness due to
hypertension is quiete high, particularly in a country where
70.2% (93.2 million) of people live below the poverty line
(earning less than US$1 (N140) per day. Urgent measures need
to be taken not only for more cost effective therapy, but also to
increase awareness and prevention of hypertension among
others.
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OBJECTIVES: To determine the relationships between patient
education and patient adherence and hypertension control in
patients in two primary care outpatient practices in an academic
medical center. METHODS: As part of an outpatient quality
measurement and improvement project, data was collected for
2003 on a random sample of 384 patients ages 45–85, through
use of billing data and medical record review. In addition to the
outcome variable of hypertension control, measured using mod-
iﬁed Health Plan Employer Data and Information Set (HEDIS)
speciﬁcations, data were collected on patient demographics, 
co-morbidities, medications, education, and adherence factors.
First, bivariate chi-square tests were performed to assess the rela-
tionship between hypertension control and each hypothesized
patient education or adherence factor. Then, a logistic regression
was performed to assess the independent relationship between
the odds of hypertension control and each patient education or
adherence factor, controlling for potentially confounding effects
of age, gender, and race. RESULTS: In the bivariate analyses, as
hypothesized, hypertension control was signiﬁcantly associated
with documented instruction/information regarding lifestyle
modiﬁcations (chi-square = 3.84, df = 1, p = 0.050), mention of
patient’s overall compliance to therapy (chi-square = 4.47, df =
1, p = 0.034), patient’s compliance to medical therapy (chi-
square = 9.11, df = 1, p = 0.002), and patient’s compliance to
lifestyle modiﬁcations (chi-square = 5.98, df = 1, p = 0.014). In
the logistic regression, while the overall model was statistically
signiﬁcant (chi-square = 17.70, df = 8, p = 0.024), none of the
hypothesized effects was signiﬁcant. However, two of the effects
approached signiﬁcance: compliance to medical therapy (chi-
square = 2.86, df = 1, p = 0.091; OR = 1.887, CI = 0.904–3.941)
and patient’s compliance to lifestyle modiﬁcations (chi-square =
2.83, df = 1, p = 0.050; OR = 2.188, CI = 0.999–4.791). CON-
CLUSIONS: Given the results of tests of hypotheses about effects
of patient education and adherence on hypertension control in
two primary care outpatient practices in an academic medical
center, additional quality improvement interventions and
research are justiﬁed to further specify the potential beneﬁts of
patient education and provider encouragement of patient 
adherence.
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OBJECTIVES: Antihypertensive medications are important in
saving lives and decreasing disability. Formulary tiers, which
determine copayment levels, may contribute to patients taking
antihypertensive medications incompletely, inconsistently, or not
at all, diminishing the potential beneﬁt of treatment. Our objec-
tive was to determine whether copayment level is related to
adherence to antihypertensive medications. METHODS: A ret-
rospective claims database evaluation of hypertensive patients in
a large health plan in Hawaii between January, 1999 and June,
2004 (n = 114,232) was conducted. Generic copayments were
$5, preferred brand copayments were $20, and copayments for
non-preferred brands varied based on price with copayments
ranging from $20–$165. Adherence was measured using med-
ication possession ratios, with a ratio of 0.8 considered adher-
ent. Adherence rates were calculated annually from the date of
ﬁrst prescription for up to three years. Multi-variable logistic
regression was used to examine the impact of copayment on
adherence, controlling for patient characteristics and speciﬁc
therapeutic class. RESULTS: Overall, adherence was 66.8% for
generics, 66.1% for preferred brands, and 54.6% for non-
preferred brands. Differences in adherence between generic 
and preferred brands for speciﬁc classes were 4–7% and 9–18%
for preferred and non-preferred brands. The largest difference in
adherence was between generic and non-preferred beta blockers
(22%). All the differences were statistically signiﬁcant at the 0.05
level. CONCLUSION: Adherence rates were consistently highest
for generic drugs, and lowest for non-preferred brands for all
speciﬁc therapeutic classes. This suggests that copayment, which
is directly tied to formulary tier, may play a signiﬁcant role in
adherence to antihypertensive medication.
